@steve10 I jumped online and you can make yourself an account...

@steve10 I jumped online and you can make yourself an account with simply just registering (No fees)
It basically looks like an update with how the company is sitting at present. ie.
Strong cash position of $15.83 million in the bank and near-term catalyst of phase 1/2 burn wound study and Phase 1 Sepsis study highlighted. No information that isn't available through announcements and that we didn't already know about.
valuation has moved from A$2.54 per share too A$2.49 but I'm guessing that projected from the cash the company has burnt this financial year.
The only thing I've taken way from it is that we're expected to burn A$6 million dollars by FY23E to put us at A8.9M

I'm not sure how accurate that is, with regards to what trials and costs are associated with the company's next moves.

I'm not expecting much more of a share price move until we either get into the higher dosing range of the sepsis trials or we get some sort of finalized data from Phase 1/2 burns trials.